Clinical Trial Update: Letermovir Use in Heart Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Letermovir use in heart transplant recipients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Disease
• Cytomegalovirus Infection
• Heart Transplantation

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Tufts Medical Center | Conditions: Cytomegalovirus Disease, Cytomegalovirus Infections | Phase 4 | Status: COMPLETED | Results posted: 2025-07-29